Suvecaltamide hydrochloride is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Myoclonic Seizure. According to GlobalData, Phase II drugs for Myoclonic Seizure have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Suvecaltamide hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Suvecaltamide hydrochloride overview

JZP-385 (CX-8998) is under development for the treatment of neurological diseases including absence seizures, childhood absence epilepsy, juvenile absence epilepsy, juvenile myoclonic epilepsy, jeavons syndrome, essential tremor, tremor associated with Parkinson's disease. It acts by targeting T Type Calcium Channel (CaV3). The drug candidate is administered through oral route.

It was also development for the treatment of schizophrenia and insomnia. 

Jazz Pharmaceuticals overview

Jazz Pharmaceuticals is a specialty biopharmaceutical company which identifies, develops, and commercializes medicines with focus on narcolepsy, cancer, pain, and psychiatry. Its marketed products include Xyrem (sodium oxybate) oral solution, Sunosi (solriamfetol), Defitelio (defibrotide sodium), Erwinaze (asparaginase erwinia chrysanthemi), Vyxeos (daunorubicin and cytarabine) liposome for injection, and others. The company also has various pipeline product candidates related to focus areas such as sleep, neurological disorders, hematology, and oncology including hematologic malignancies and solid tumors. The company sells its products through a network of local distributors and wholesalers. It has operations in the US and Europe. Jazz Pharmaceuticals is headquartered in Dublin, Ireland.

For a complete picture of Suvecaltamide hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.